Introduction
Multiple myeloma (MM) is a malignant clonal B-Iymphoproliferative disease. Survival ranges from a few months to many years [7] . The determination of prognosis for the disease's course is important in therapeutic choice. At least two factors determine the course of MM:
1) the biology of myeloma cells and 2) the interrelation of malignant cells and host organism.
That is why the morphology of myeloma cells is one of the most important prognostic factors of the disease [4] . There are also other prognostic factors associated with both malignant cell characteristics and the status of the host's immunocompetent system [7] . Taking into account the data on the decrease in colony-forming units -granulocyte/macrophage (CFU-OM) in MM [2, 11] , an~ the antitumor effect of tumor necrOSIS factor alpha (TN Fa) [8, 9] and interleukin-2 (1L-2) [10] , we investigated myeloma cell morphology, the level of serum P2-microglobulin (SP2-M) and CFU-OM, TNF production by peripheral blood monocytes, and IL-2 production by peripheral blood mononuclear cells in different types ofMM course in order to determine their prognostic significance.
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Materials and Methods
We investigated 101 patients with MM. Diagnosis was made according to previously described criteria [5] .
Clinical Classification. It is impossible to predict individual prognosis in MM according to the stage of the disease [6] at the first presentation. That is why we classified our patients according to their life duration, which determined the type of the disease. This classification is a result of prospective investigation. We divided the patients into three groups: first -indolent myeloma, second -active myeloma, third -aggressive myeloma.
The diagnosis was made on the following criteria:
1) Indolent myeloma. Patients who presented with Kyle's criteria [7] , patients who had been in remission for more than 5 years without chemotherapy, and patients with monoclonal gammopathy ofundetermine~ signi~ca~ce who had been under InvestIgatIOn from 2 to 5 years ( Fig. 1 Morphological Classification. The degree of myeloma cell maturation :was ~ete~ mined according to the followmg cntena
90 ' I, 1) mature -comprising more than 50 % mature plasma cells; 2) immature -comprising more than 50 % proplasmacytes and mixed cell myeloma where none of the morphologically distinct plasma cell types exceed 50 % (the proportion of lymphoplasmacytoid cells was always less than 50 % of the bone marrow plasma cells); 3) plasmablastic -comprising more than 50 % plasmablasts.
Serum P2-Microglobulin. SP2-M was measured by 125 1 radioimmunoassay.
Colony-Forming Unit-Granulocyte/Macrophage. The cloning of hemopoietic cells was performed in a agar drop-liquid medium system [1] .
Biological Activity ofIL-2. The biological activity of IL-2 in conditioned media of peripheral blood mononuclear cells was assayed according to the method reported by Bockman and Ropo [3] .
TNF a Activity. The spontaneous and pyrogen-stimulated (50 Ili/ml) production of TNF a by peripheral blood monothe active course, the line of dashes, the aggressive course cytes was assayed by exploring the immunoenZyme kits (performed by the Institute of High Purified Preparations (HPP) Leningrad, USSR), based on monoclonal and polyclonal antibodies to TNF a' In order to form the calibration curve in each case TNF a was used (made by NPO "Ferment", Tallin, USSR).
Results
It was revealed that mature plasma cells were the morphological substrate in indolent myeloma (Fig. 2) at the same time in active myeloma, mature cells predominated in 77% of the patients, whereby in the remaining 23 % of the patients, the cells were immature. In aggressive myeloma, immature cells were the main morphological type in 56.3 % of the patients, plasmablasts prevailed in 37.5 % of the patients, and mature cells were in 6.2 % of the patients.
We discovered that the level of SP2-M correlated with the course ofMM in most of the patients (Fig. 3 ). There was a significant difference between the level of SP2-M in patients with indolent myeloma There was also significant difference between the level of SP2-M in patients with active and aggressive myeloma (8.6 + 1.2 mg/l; p < 0.05) and a significant difference between patients with aggressive and indolent courses (p < 0.01; Fig. 4) .
Studies on the c1onogenic ability of CFU-GM in patients with an indolent course gave unusual results. In most patients with an indolent course, the number of CFU-GM was higher than in healthy controls (Fig. 5) . The number of colony-forming cells in agar culture ranged from 30 to 300 per 10 5 bone 52 marrow cells, whereas in normal bone marrow cells it ranged from 40 to 60 per 10 5 bone marrow cells. High levels of CFU-GM were also found in some patients with active myeloma as compared with healthy controls. The number of colony-forming cells in agar culture in active myeloma ranged from 42 to 420 per 10 5 bone marrow cells. In patients with aggressive myeloma the number of colony-forming cells in agar culture ranged from 0 to 25 per 10 5 bone marrow cells, which was much less than in patients with indolent and active myeloma and less than in normal controls.
There was an insignificant difference in IL-2 production between healthy conthe course Sp~M[mQ/l] (Figs. 6, 7 ) and active courses (11.9 + 0.7 units of activity) and between the indolent and active courses. Then significant differences were found in the IL-2 production between patients with active and aggressive myeloma (8.6+0.6 units of activity; An insignificant difference between the pyrogen-stimulated production of TNF a in patients with an indolent course (1.5 + 0.3 ng/ml) and healthy controls (2.2 + 0.38 ng/ml) was detected (p> 0.05; Fig. 8) .
A significant difference was found between the pyrogen-stimulated production of TNF a in patients with indolent and active courses (6.1 + 1.1 ng/ml; p < 0.01). There was also a significant different in TNFa production between patients with active myeloma and healthy controls (p < 0.05), and also in TNFa production in patients with active and aggressive myeloma (2.0 + 1.2 ng/ml; p < 0.05). There was an insignificant difference between TNFa production in patients with aggressive and indolent courses and healthy controls (p > 0.05; Fig. 9 ).
•• 
Conclusion
Our data suggest that:
1) Morphology of myeloma cells is the most important prognostic factor which, without a doubt, can be easily reproduced, and is widely used in clinical practice. The studies mentioned above were necessary in order to find out the role of these factors in MM pathogenesis. 
